Early Childhood Exposure to Aluminum- Absorbed Vaccines Poses No Risks

A recent study shows early childhood exposure to aluminum-adsorbed vaccines is not associated with an increased risk for autoimmune, atopic or allergic, or neurodevelopmental disorders. 

In the study, researchers examined the association in Denmark from 1997 to 2020. Participants included 1,224,176 children born in Denmark between 1997 and 2018 who were alive and resided in the country at age 2 years. Results showed no association for cumulative aluminum exposure from vaccination during the first two years of life with increased rates of any of the 50 chronic disorders assessed, including autism. Per 1 mg increase in aluminum exposure, adjusted hazard ratios were 0.98 (95 percent confidence interval [CI], 0.94 to 1.02) for any autoimmune disorder, 0.99 (95 percent CI, 0.98 to 1.01) for any atopic or allergic disorder, and 0.93 (95 percent CI, 0.90 to 0.97) for any neurodevelopmental disorder. The upper bounds of the 95 percent confidence intervals were incompatible with relative increases greater than 10 or 30 percent for most individually analyzed outcomes.

According to the researchers, “Findings were incompatible with moderate-to-large relative increases in the risks for autoimmune, atopic or allergic, and neurodevelopmental disorders associated with early childhood exposure to aluminum-adsorbed vaccines for most outcomes, although small relative increases could not be statistically excluded, particularly for some rarer outcomes.”